Charles Watson Moore

703 total citations
9 papers, 450 citations indexed

About

Charles Watson Moore is a scholar working on Organic Chemistry, Oncology and Molecular Biology. According to data from OpenAlex, Charles Watson Moore has authored 9 papers receiving a total of 450 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Organic Chemistry, 5 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in Charles Watson Moore's work include Metal complexes synthesis and properties (3 papers), Ferrocene Chemistry and Applications (2 papers) and Synthesis and biological activity (2 papers). Charles Watson Moore is often cited by papers focused on Metal complexes synthesis and properties (3 papers), Ferrocene Chemistry and Applications (2 papers) and Synthesis and biological activity (2 papers). Charles Watson Moore collaborates with scholars based in United States and New Zealand. Charles Watson Moore's co-authors include Alan J. Kraker, A J Kraker, Mark R. Barvian, Hollis D. Showalter, Brian G. Hartl, Aneesa M. Amar, William A. Denny, William L. Elliott, Randall W. Steinkampf and Jeff B. Smaill and has published in prestigious journals such as Journal of Medicinal Chemistry, Biochemical Pharmacology and Cancer Letters.

In The Last Decade

Charles Watson Moore

9 papers receiving 428 citations

Peers

Charles Watson Moore

ONCOL

HEMAT

PFM

Marcel Koenig United States

Todd Miller United States

Douglas W. Beight United States

David J. Calderwood United States

Anand Sistla United States

James M. Hamby United States

Mauro Angiolini Italy

Tony C. Luu United States

Brian L. Batley United States

Asaad Nematalla United States

Marcel Koenig United States

Charles Watson Moore

281 ×1.4

121 ×0.7

150 ×1.0

ONCOL

43 ×0.8

HEMAT

47 ×1.0

PFM

Citations per year, relative to Charles Watson Moore Charles Watson Moore (= 1×) peers Marcel Koenig

Countries citing papers authored by Charles Watson Moore

Since Specialization

Citations

This map shows the geographic impact of Charles Watson Moore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Watson Moore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Watson Moore more than expected).

Fields of papers citing papers by Charles Watson Moore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Watson Moore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Watson Moore. The network helps show where Charles Watson Moore may publish in the future.

Co-authorship network of co-authors of Charles Watson Moore

This figure shows the co-authorship network connecting the top 25 collaborators of Charles Watson Moore. A scholar is included among the top collaborators of Charles Watson Moore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Watson Moore. Charles Watson Moore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Palmer, Brian D., Jeff B. Smaill, Gordon W. Rewcastle, et al.. (2005). Structure–activity relationships for 2-anilino-6-phenylpyrido[2,3-d]pyrimidin-7(8H)-ones as inhibitors of the cellular checkpoint kinase Wee1. Bioorganic & Medicinal Chemistry Letters. 15(7). 1931–1935. 54 indexed citations

Palmer, Brian D., Jeff B. Smaill, Gordon W. Rewcastle, et al.. (2005). Structure—Activity Relationships for 2‐Anilino‐6‐phenylpyrido[2,3‐d]pyrimidin‐7(8H)‐ones as Inhibitors of the Cellular Checkpoint Kinase Wee1.. ChemInform. 36(31). 2 indexed citations

Schroeder, Mel C., James M. Hamby, Cleo J. C. Connolly, et al.. (2001). Soluble 2-Substituted Aminopyrido[2,3-d]pyrimidin-7-yl Ureas. Structure−Activity Relationships against Selected Tyrosine Kinases and Exploration of in Vitro and in Vivo Anticancer Activity. Journal of Medicinal Chemistry. 44(12). 1915–1926. 49 indexed citations

Kraker, Alan J., Brian G. Hartl, Aneesa M. Amar, et al.. (2000). Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Biochemical Pharmacology. 60(7). 885–898. 121 indexed citations

Showalter, H. D. Hollis, Anthony D. Sercel, William L. Elliott, et al.. (1997). Tyrosine Kinase Inhibitors. 6. Structure−Activity Relationships among N- and 3-Substituted 2,2‘-Diselenobis(1H-indoles) for Inhibition of Protein Tyrosine Kinases and Comparative in Vitro and in Vivo Studies against Selected Sulfur Congeners. Journal of Medicinal Chemistry. 40(4). 413–426. 57 indexed citations

Kraker, Alan J., Charles Watson Moore, Billy Roberts, Wilbur R. Leopold, & William L. Elliott. (1991). Preclinical antitumor activity of CI-973,[SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)] (2 methyl-1,4-butane-diamine-N,N′)platinum. Investigational New Drugs. 9(1). 1–8. 9 indexed citations

Kraker, Alan J. & Charles Watson Moore. (1988). Elevated DNA polymerase beta activity in a cis-diamminedichloroplatinum(II) resistant P388 murine leukemia cell line. Cancer Letters. 38(3). 307–314. 42 indexed citations

Kraker, A J & Charles Watson Moore. (1988). Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro.. PubMed. 48(1). 9–13. 102 indexed citations

Moore, Charles Watson. (1965). You Have to Pay for the Public Life. Perspecta. 9. 57–57. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact